Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Expected to Announce Quarterly Sales of $408.14 Million

Equities analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report $408.14 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Jazz Pharmaceuticals PLC’s earnings, with the highest sales estimate coming in at $410.72 million and the lowest estimate coming in at $405.20 million. Jazz Pharmaceuticals PLC posted sales of $381.16 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.1%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that Jazz Pharmaceuticals PLC will report full-year sales of $408.14 million for the current year, with estimates ranging from $1.64 billion to $1.66 billion. For the next year, analysts forecast that the business will post sales of $1.92 billion per share, with estimates ranging from $1.85 billion to $2.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing analysts’ consensus estimates of $1.42 by $0.01. The company had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.26 EPS.

A number of equities research analysts have recently issued reports on the company. Vetr raised Jazz Pharmaceuticals PLC from a “buy” rating to a “strong-buy” rating and set a $161.19 target price on the stock in a research report on Monday, April 3rd. Deutsche Bank AG reaffirmed a “buy” rating and set a $176.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. TheStreet raised Jazz Pharmaceuticals PLC from a “c+” rating to a “b-” rating in a research report on Tuesday, March 28th. Cowen and Company reaffirmed a “positive” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Monday, March 20th. Finally, BMO Capital Markets reaffirmed a “positive” rating and set a $192.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Monday, March 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $182.46.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/08/09/jazz-pharmaceuticals-plc-nasdaqjazz-expected-to-announce-quarterly-sales-of-408-14-million-updated-updated-updated.html.

In other Jazz Pharmaceuticals PLC news, SVP Karen J. Wilson sold 1,275 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $160.00, for a total value of $204,000.00. Following the transaction, the senior vice president now directly owns 21,133 shares in the company, valued at approximately $3,381,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Suzanne Sawochka Hooper sold 2,500 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $160.00, for a total value of $400,000.00. Following the completion of the transaction, the executive vice president now owns 39,649 shares in the company, valued at $6,343,840. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,295 shares of company stock worth $6,516,538. 4.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc purchased a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $205,000. Bridges Investment Management Inc. purchased a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $208,000. Private Advisor Group LLC purchased a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $215,000. Finally, Mn Services Vermogensbeheer B.V. raised its position in shares of Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.59% during mid-day trading on Wednesday, hitting $154.47. The company had a trading volume of 292,353 shares. The company has a market cap of $9.27 billion, a PE ratio of 23.34 and a beta of 1.11. The company’s 50 day moving average price is $151.80 and its 200-day moving average price is $138.04. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals PLC (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply